Sign in
Taking people in United StatesPhase 2

Duvakitug for adults with moderate to severe hidradenitis suppurativa

Tests different doses of duvakitug against placebo in adults with hidradenitis suppurativa.

Key facts

Who runs it
Sanofi
Where
Birmingham and Miami, United StatesSee the 2 sitesAlso in 1 other country, 2 sites
Trial code
Registry title
A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Status
Recruiting
Phase
Phase 2
People taking part
156 people, planned
Started
19 Oct 2026
Expected to end
8 Nov 2030
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Duvakitug
  • Placebo
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe hidradenitis suppurativa (HS), a long-lasting skin disease with painful lumps and abscesses. It tests duvakitug against placebo.

Age
18 years and older
Sex
All sexes
Disease stage
Moderate to severe HS for at least 6 months. Lesions in at least 2 separate body areas, with at least 1 area at Hurley Stage II or III. A total of 5 or more abscesses and inflamed lumps (AN count ≥5) at the Baseline Visit.
Earlier treatment
Antibiotic pills or injections for HS did not work well enough, HS came back after stopping them, they were not tolerated, or they cannot be used. People who never had a biologic or immunosuppressive small molecule drug for HS can join. People who had at least 1 such drug can also join.

Main reasons for not taking part

  • Another active skin disease or infection that may disturb the HS checks
  • Serious allergic reaction to any biologic therapy
  • Repeated or recent serious infection, or a weak immune system
  • Solid organ or stem cell transplant, or spleen removal
  • Cancer within 5 years before screening, except some fully removed skin or cervical cancers

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Participants with a history of signs and symptoms consistent with hidradenitis suppurativa (HS) for at least 6 months prior to Baseline Visit
  • Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left, and right axilla; or left axilla and left inguino-crural fold), with at least 1 body site being Hurley Stage II or III
  • Participant must have a total abscess and inflammatory nodule (AN) count of ≥5 at the Baseline Visit
  • Participants must have had an inadequate response to a course of a systemic antibiotics for treatment of HS, exhibited recurrence after discontinuation of antibiotics or demonstrated intolerance to antibiotics, or has a contraindication to systemic antibiotics for treatment of their HS as assessed by the Investigator through participant interview and review of medical history
  • Participants must have a prior HS treatment history consistent with the following:; For the biologic and immunosuppressive small molecule-naïve subgroup, participants must have no history of treatment with any approved or investigational biologic therapy or small molecule immunosuppressive therapy with potential efficacy for HS; For the biologic and immunosuppressive small molecule-experienced subgroup, participants must have a history of treatment with at least 1 biologic or immunosuppressive small molecule therapy with potential efficacy for HS

Who cannot take part

  • History within the 2 years prior to Baseline Visit of prescription drug or substance abuse, including alcohol, considered significant by the Investigator
  • Any other medical condition or severe, concomitant illness, including psychiatric illness and substance abuse, that may present an unreasonable risk to the study participants, make participants unreliable, or may interfere with study assessments; The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
  • Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS
  • History of systemic hypersensitivity or anaphylaxis to any biologic therapy
  • History of recurrent or recent serious infection
  • Known history of or suspected significant current immunosuppression
  • History of solid organ transplant or stem cell transplant
  • History of splenectomy
  • History of malignancy or suspicion of malignancy within 5 years prior to the Screening Visit (except for in situ cervical carcinoma that has been treated by surgery and completely cured, or basal cell carcinoma or squamous cell carcinoma that has been excised and completely cured)
  • Any medical or psychiatric condition which, in the opinion of the Investigator could be considered uncontrolled, unstable, or likely to progress in a clinically relevant manner and may present an unreasonable risk to the study participants as a result of his/her participation in this clinical study, may make participant's participation unreliable, or may interfere with study assessments
  • Participants are excluded from the study if any of the following criteria apply:

Where in United States

Also in 1 other country, 2 sites

  • Cahaba Dermatology & Skin Health Center- Site Number : 8400004Birmingham, United StatesTaking people
  • Florida International Research Center- Site Number : 8400002Miami, United StatesTaking people

About the trial

What the trial wants to find out

This is a parallel, Phase 2b, 3-arm, double-blind, randomized, multicenter, multinational, placebo-controlled, dose-ranging study to evaluate the efficacy and the safety of different doses of duvakitug in adult participants with moderate to severe hidradenitis suppurativa.

Read full original descriptionShow less

Study details include:

* The study duration will be up to 145 weeks , including a 4-week screening period, a 16-week initial double-blind treatment period, a 24-week active blinded extension period, a 96-week long-term extension period and a 5-week follow-up period. * The treatment duration will be up to 40 weeks for the participants who will stop after the active blinded extension period and up to 136 weeks for the participants who will continue in the long-term extension period. * The number of visits will be up to 23 for the participants who will stop after the active blinded extension period and up to 71 for the participants who will continue in the long-term extension period.

The 3 groups in the trial

  • Duvakitug Dose Regimen ATreatment being tested

    Participants will receive Duvakitug dose regimen A as per protocol

    Treatment: Duvakitug

  • Duvakitug Dose Regimen BTreatment being tested

    Participants will receive Duvakitug dose regimen B as per protocol

    Treatment: Duvakitug

  • PlaceboPlacebo, for comparison

    Participants will receive Duvakitug matching placebo as per protocol

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Plain-language title
Duvakitug for adults with moderate to severe hidradenitis suppurativaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
9 November 2026